'Dose levels' diaporamas de présentation

Part 3

Part 3. IAEA Training Material on Radiation Protection in Nuclear Medicine. Principles of radiation protection and the international framework Regulatory requirements. Objective.

1.87k views • 156 slides

Common Drugs - Dosing and Monitoring

Common Drugs - Dosing and Monitoring . Toxic? Me? With My Therapeutic Window?. PHENYTOIN. Introduction.

1.94k views • 90 slides

764 views • 45 slides

Implementation of Bayesian Logistic Regression for dose escalation at Novartis Oncology

Implementation of Bayesian Logistic Regression for dose escalation at Novartis Oncology. Glen Laird, Novartis Oncology Workshop in Phase I designs October 2, 2009 With contributions from Beat Neuenschwander, Bill Mietlowski, Jyotirmoy Dey, and Stuart Bailey. Outline of Presentation.

1.7k views • 45 slides

Satoshi Morita Dept. of Biostatistics and Epidemiology, Yokohama City University Medical Center

Practical Application of the C ontinual R eassessment M ethod to a Phase I Dose-Finding Trial in Japan: East meets West. Satoshi Morita Dept. of Biostatistics and Epidemiology, Yokohama City University Medical Center.

564 views • 41 slides

Chris Town Research Pharmacokinetics

A Short Course in Pharmacokinetics. Chris Town Research Pharmacokinetics. Outline. Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why do Drug Candidates fail? Processes involved in PK Absorption PK study example

698 views • 39 slides

Pharmacodynamic Paradigms in Early-Phase Cancer Clinical Trials

Pharmacodynamic Paradigms in Early-Phase Cancer Clinical Trials. Workshop Phase 0 Trials In Oncologic Drug Development. Hilary Calvert Northern Institute for Cancer Research. Methodology for Phase I and Phase 0 (translational) Trials.

1.03k views • 34 slides

Drug discovery and development

Drug discovery and development. Ian Hughes, i.e.hughes@leeds.ac.uk Objectives of next 5 lectures: you will: be aware of why/how new drugs are discovered know the processes involved in drug discovery and development see where pharmacologists/bioscientists may contribute

1.15k views • 31 slides

Drug discovery and development

Drug discovery and development. Ian Hughes, i.e.hughes@leeds.ac.uk Objectives of next 5 lectures: you will: be aware of why/how new drugs are discovered know the processes involved in drug discovery and development see where pharmacologists/bioscientists may contribute

755 views • 31 slides

Drug discovery and development

Drug discovery and development. Ian Hughes, i.e.hughes@leeds.ac.uk Objectives of next 5 lectures: you will: be aware of why/how new drugs are discovered know the processes involved in drug discovery and development see where pharmacologists/bioscientists may contribute

1.07k views • 31 slides

Stem Cells in cardiovascular diseases

Stem Cells in cardiovascular diseases. Arshed A. Quyyumi MD; FRCP Professor of Medicine Division of Cardiology Emory University School of Medicine. Atlanta, Georgia, USA. Disclosure of Financial Relationships.

589 views • 31 slides

Peto Trend Test: Investigating The Impact Of Tumor Misclassification

739 views • 28 slides

Optimal GNG decision rules for an adaptive seamless Ph2/3 oncology trial

Optimal GNG decision rules for an adaptive seamless Ph2/3 oncology trial . Cong Chen Linda Sun BARDS, Merck & Co., Inc. Typical situation in oncology. Success rate in Ph3 is low, cost for Ph3 is high and competition is fierce Data at Ph2 to Ph3 transition point

302 views • 27 slides

597 views • 23 slides

Managing your OR imaging dose . August, 2011

Surgery. Managing your OR imaging dose . August, 2011. Surgery. Dose makes headlines. Surgery. A s. Delivering the proper amount of radiation is critical to producing superb image quality . L ow. A s. R easonably. A chievable . Surgery. Why should we care about dose?.

347 views • 23 slides

Next steps in the validation of the pubertal assays

Next steps in the validation of the pubertal assays Issues, questions, plans J. Kariya OSCP/USEPA December 11, 2003 Initial questions for EDMVS

775 views • 22 slides

557 views • 22 slides

Linear No-Threshold Model

Linear No-Threshold Model. Michela Paganini Physics H190 - Spring 2012. Definition. The LINEAR NO-THRESHOLD MODEL (LNT) is a model used in radiation protection to estimate the long-term, biological damage caused by ionizing radiation

232 views • 22 slides

Sotalol

370 views • 21 slides

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial. Shivaani Kummar, MD National Cancer Institute September 5, 2007. Objectives. Primary :

317 views • 15 slides